Sino Biopharmaceutical CEO Eric Tse framed China's rapid clinical trial expansion as a matter of survival for the industry, speaking with Bloomberg TV's Haslinda Amin at the 2026 World Economic Forum in Davos. He emphasized that accelerating trial timelines is now essential for maintaining global competitiveness and meeting domestic healthcare demands.

Tse outlined an open-ended approach to deal-making in 2026, suggesting Sino Biopharma will remain flexible in its partnerships and acquisitions. This strategy aligns with a broader trend of Chinese biotech firms seeking external innovation to bolster pipelines, as domestic growth rates in the sector begin to mature and competition intensifies globally.

The comments come as China's clinical trial approvals have surged, reflecting a push to reduce regulatory bottlenecks. Investors will watch how Sino Biopharma's deal strategy translates into tangible asset acquisitions or licensing agreements, which could significantly impact its valuation and market position in the coming year.